PolyNovo share price jumps despite the market selloff amid heavy insider buying

The S&P/ASX 200 Index (ASX: XJO) is a sea of red on Friday but that hasn't stopped the PolyNovo Ltd (ASX: …

| More on:
A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The PolyNovo share price is charging higher despite the market selloff
  • News of insider buying appears to have boosted the medical device company's shares
  • PolyNovo's chair picked up 500,000 shares through an on-market trade on Thursday

The S&P/ASX 200 Index (ASX: XJO) is a sea of red on Friday but that hasn't stopped the PolyNovo Ltd (ASX: PNV) share price from charging higher.

In afternoon trade, the medical device company's shares are up 6% to 92 cents.

Why is the PolyNovo share price racing higher?

The PolyNovo share price has avoided the market selloff today after it emerged that insiders have been buying the company's shares.

According to two change of director's interest notices, PolyNovo's chairman and a non-executive director have both been buying shares.

The first notice reveals that chairman David Williams picked up 500,000 shares through an on-market trade on Thursday. Mr Williams paid an average of $0.8689 per share, which represents a total consideration of $434,450.

The other notice shows that non-executive director Andrew Lumsden bought 100,000 shares through an on-market trade on the same day. Mr Lumsden paid an average of $0.8731 per share, which represents a total consideration of $87,310.

Based on these purchases, these insiders appear to believe the PolyNovo share price is good value after hitting a multi-year low of 84 cents earlier this week.

Analysts at Macquarie are likely to agree with that view. Last month, the broker put an outperform rating and $1.60 price target on the company's shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »